CXL Ophthalmics is currently developing minimally invasive treatment options for patients with corneal disease.
Dr. Talamo worked in clinical practice for 25 years, specializing in corneal disease, cataract and refractive surgery, according to a Jan. 18 press release.
He then became chief medical officer at Ocular Therapeutix and chief medical officer and worldwide vice president of clinical and medical affairs at Johnson & Johnson.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.